Last reviewed · How we verify
NCT05470894
Liver Injury After COVID-19 Vaccination
trial testing Approved COVID-19 vaccine in Subjects After COVID-19 Vaccination in 379 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Humanity & Health Medical Group Limited |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 379 |
| Start date | 5 September 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 3 locations across Hong Kong, Japan |
Drugs / interventions tested
- Approved COVID-19 vaccine — full drug profile →
Conditions studied
- Subjects After COVID-19 Vaccination — all drugs for Subjects After COVID-19 Vaccination →
Sponsor
Humanity & Health Medical Group Limited — full company profile →
Who can join
5 and older, any sex, with Subjects After COVID-19 Vaccination. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is still raging across the world and vaccination is expected to lead us out of this pandemic. Although the efficacy of these vaccines is beyond doubt, safety still remains a concern. Liver injury, such as autoimmune hepatitis (AIH), has been reported after COVID-19 vaccination. The aim of this prospective study is to investigate the spectrum and profile of liver injury after COVID-19 vaccination in Asia-Pacific region and to explore the potential risk factors for the development of liver injury.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05470894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Humanity & Health Medical Group Limited trials
Trials by the same sponsor.
- NCT04428437 — Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors · terminated
- NCT04775069 — Antibody Response to COVID-19 Vaccines in Liver Disease Patients · Phase 4 · completed
- NCT03899428 — Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC · Phase 2 · recruiting
- NCT03794258 — Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection · Phase 2 · withdrawn
- NCT03792919 — Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK) · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05470894 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Humanity & Health Medical Group Limited
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05470894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing